Skip to main content
. 2012 Sep 12;38(2):302–312. doi: 10.1038/npp.2012.171

Figure 2.

Figure 2

(a) Ex vivo [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3′-iodo-2′-propenyl)amino] tetralin ([125I]7OH-PIPAT) binding to representative, coronal, one-hemisphere brain sections from rats treated with vehicle or GSK598809 (3 mg/kg, intraperitoneally (i.p.)). (b) Occupancy of [125I]7OH-PIPAT binding sites (=OD3R) in the rat shell of the nucleus accumbens (AcbSh) at increasing blood (● ng/ml) and brain (○ ng/g) GSK598809 concentrations, 1 h after administration of GSK598809 (0.05–3 mg/kg intraperitoneally). (c) Time–course of the OD3R in the rat AcbSh (●) after a single administration of GSK598809 (1 mg/kg intraperitoneally); the figure also shows GSK598809 concentration in the blood (dotted line; ng/ml) and brain (dashed line; ng/g).